BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd., a subsidiary of Bausch...
BioCentury | Aug 9, 2019
Finance

Stem cells (re)generate rewards for Versant, Bayer

...regenerative medicine was “out of favor,” thanks to events such as the mid-2016 closure of StemCells Inc....
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
BioCentury | Feb 8, 2017
Distillery Techniques

Disease models

TECHNOLOGY: 3D models Fundus organoids derived from human pluripotent stem cells could be used to screen therapies for peptic ulcers and other gastric diseases. The organoids were generated by culturing human pluripotent stem cells in...
BioCentury | Jan 5, 2017
Translation in Brief

Nervous gut

Researchers at Cincinnati Children’s Hospital Medical Center have developed the first human intestinal organoid model with a functioning enteric nervous system. The model not only provides a more complete picture of human gastrointestinal (GI) physiology...
BioCentury | Dec 30, 2016
Company News

Cincinnati Children's Hospital, StemCell deal

The hospital granted StemCell exclusive rights to commercialize technology that allows for the generation of gastrointestinal organoids from human pluripotent stem cells. Specifically, StemCell gained IP for intestinal and stomach organoid models, plus rights to...
BioCentury | Dec 22, 2016
Finance

Starting up stem cells

...unsure regulatory landscape and the shadow of recent failures, such as the June closure of StemCells Inc....
BioCentury | Nov 4, 2016
Strategy

The next (re)generation

...a warning that the field is not yet ready to sustain viable companies. In June, StemCells Inc....
...N.C. RegenMedTX Inc., Winston-Salem, N.C. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Semma Therapeutics Inc., Cambridge, Mass. StemCells Inc....
BioCentury | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Not applicable

Genitourinary disease INDICATION: Incontinence; pain; spinal cord injury (SCI) Mouse studies suggest medial ganglionic eminence-like cell transplants could help treat incontinence and pain associated with SCI. In a mouse model of thoracic SCI, transplant of...
BioCentury | Oct 4, 2016
Company News

Management tracks

...company Lion Biotechnologies Inc. (NASDAQ:LBIO) named Gregory Schiffman CFO. He was EVP and CFO at StemCells Inc....
Items per page:
1 - 10 of 335
BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd., a subsidiary of Bausch...
BioCentury | Aug 9, 2019
Finance

Stem cells (re)generate rewards for Versant, Bayer

...regenerative medicine was “out of favor,” thanks to events such as the mid-2016 closure of StemCells Inc....
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
BioCentury | Feb 8, 2017
Distillery Techniques

Disease models

TECHNOLOGY: 3D models Fundus organoids derived from human pluripotent stem cells could be used to screen therapies for peptic ulcers and other gastric diseases. The organoids were generated by culturing human pluripotent stem cells in...
BioCentury | Jan 5, 2017
Translation in Brief

Nervous gut

Researchers at Cincinnati Children’s Hospital Medical Center have developed the first human intestinal organoid model with a functioning enteric nervous system. The model not only provides a more complete picture of human gastrointestinal (GI) physiology...
BioCentury | Dec 30, 2016
Company News

Cincinnati Children's Hospital, StemCell deal

The hospital granted StemCell exclusive rights to commercialize technology that allows for the generation of gastrointestinal organoids from human pluripotent stem cells. Specifically, StemCell gained IP for intestinal and stomach organoid models, plus rights to...
BioCentury | Dec 22, 2016
Finance

Starting up stem cells

...unsure regulatory landscape and the shadow of recent failures, such as the June closure of StemCells Inc....
BioCentury | Nov 4, 2016
Strategy

The next (re)generation

...a warning that the field is not yet ready to sustain viable companies. In June, StemCells Inc....
...N.C. RegenMedTX Inc., Winston-Salem, N.C. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Semma Therapeutics Inc., Cambridge, Mass. StemCells Inc....
BioCentury | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Not applicable

Genitourinary disease INDICATION: Incontinence; pain; spinal cord injury (SCI) Mouse studies suggest medial ganglionic eminence-like cell transplants could help treat incontinence and pain associated with SCI. In a mouse model of thoracic SCI, transplant of...
BioCentury | Oct 4, 2016
Company News

Management tracks

...company Lion Biotechnologies Inc. (NASDAQ:LBIO) named Gregory Schiffman CFO. He was EVP and CFO at StemCells Inc....
Items per page:
1 - 10 of 335